[BCLI] Brainstorm Cell Therapeutics Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 2.58 Change: 0.08 (3.2%)
Ext. hours: Change: 0 (0%)

chart BCLI

Refresh chart

Description: Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson?s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company?s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.27 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-16.37
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-41.86% ROE-47.66% ROI
Current Ratio8.1 Quick Ratio Long Term Debt/Equity Debt Ratio0.14
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities14.74 M Cash From Investing Activities-13.56 M Cash From Operating Activities-1.94 M Gross Profit
Net Profit-2.24 M Operating Profit-2.21 M Total Assets22.39 M Total Current Assets22.08 M
Total Current Liabilities2.73 M Total Debt Total Liabilities2.73 M Total Revenue
Technical Data
High 52 week4.48 Low 52 week2.98 Last close3.93 Last change3.97%
RSI64.71 Average true range0.14 Beta0.22 Volume94.48 K
Simple moving average 20 days4.54% Simple moving average 50 days1.75% Simple moving average 200 days0.66%
Performance Data
Performance Week2.08% Performance Month0.77% Performance Quart9.78% Performance Half5.36%
Performance Year22.43% Performance Year-to-date10.7% Volatility daily2.38% Volatility weekly5.33%
Volatility monthly10.92% Volatility yearly37.83% Relative Volume272.01% Average Volume54.78 K
New High New Low


2020-05-27 07:25:00 | BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research

2020-05-18 06:06:37 | Does The Brainstorm Cell Therapeutics Inc. NASDAQ:BCLI Share Price Tend To Follow The Market?

2020-05-08 05:35:00 | BCLI: The Countdown to Phase 3 ALS Data Begins…

2020-05-07 06:30:10 | BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update

2020-05-07 01:00:10 | BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union

2020-05-04 03:30:10 | BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology

2020-04-29 06:00:10 | BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update

2020-04-08 06:40:00 | BCLI: $1.5M Grant from Israel Innovation Authority…

2020-04-03 06:59:09 | BrainStorm Awarded $1.5 Million Non-Dilutive Grant for 2020 by the Israel Innovation Authority

2020-04-01 09:00:10 | David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer

2020-03-31 04:00:10 | BrainStorm Appoints Renowned Distinguished Economist, Prof. Jacob Frenkel, Chairman of the Board of Directors

2020-03-16 03:00:10 | BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

2020-03-06 09:25:10 | BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share

2020-02-27 01:00:10 | Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

2020-02-20 05:10:00 | BCLI: Phase 3 ALS Results in 4Q20…

2020-02-18 07:00:10 | BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2019

2020-02-18 06:00:00 | Brainstorm Cell Therapeutics, Inc. to Host Earnings Call

2020-02-17 01:00:10 | BrainStorm’s Chief Operating Officer to Present at Noble Capital Markets’ Sixteenth Annual Investor Conference

2020-02-11 06:00:10 | BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS

2020-02-10 01:00:10 | BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

2020-02-04 04:45:10 | BrainStorm CEO to Provide Company Update at the BIO CEO & Investor Conference

2020-01-29 04:00:10 | BrainStorm Receives Notice of Intention to Grant Additional EU patent for NurOwn®

2020-01-21 09:53:06 | BrainStorm Cell Therapeutic’s COO and CMO, Dr. Ralph Kern, to Present at the 10th Annual California ALS Research Summit

2020-01-17 06:00:08 | How Many Brainstorm Cell Therapeutics Inc. NASDAQ:BCLI Shares Did Insiders Buy, In The Last Year?

2020-01-07 01:00:10 | BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

2020-01-03 10:21:24 | Weekly CFO Buys Highlight

2019-12-19 05:00:10 | NurOwn® Data Safety Monitoring Board Recommends MS Phase 2 Clinical Trial Continue

2019-12-18 05:00:10 | BrainStorm Issues 2019 Letter to Shareholders

2019-12-11 05:00:10 | BrainStorm Selected as Buzz of BIO 2020 Winner

2019-11-26 08:05:45 | BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND

2019-11-25 06:00:10 | BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site

2019-11-21 06:15:00 | BCLI: Phase 3 ALS Trial Fully Enrolled; Phase 2 Results Published in Neurology…

2019-11-20 07:00:00 | BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology

2019-11-18 06:32:43 | Does Brainstorm Cell Therapeutics Inc. NASDAQ:BCLI Have A High Beta?

2019-11-14 08:07:04 | The Daily Biotech Pulse: Amarin Braces For Vascepa Adcom Verdict, Biotechs On A Fundraising Spree, Zosano Makes Progress With Migraine Drug Filing

2019-11-14 07:00:00 | BrainStorm Cell Therapeutics Announces Research Grant Award From the National Multiple Sclerosis Society

2019-11-14 06:00:00 | BrainStorm Announces Financial Results for the Third Quarter of 2019 and Provides a Corporate Update

2019-11-13 05:00:00 | BrainStorm Announces Grant of a New Japanese Patent for NurOwn®

2019-11-12 01:00:00 | BrainStorm Cell Therapeutics Announces Ralph Kern MD MHSc to Present at the 7th International Stem Cell Meeting

2019-11-05 06:15:00 | BrainStorm Cell Therapeutics to Announce Third Quarter Financial Results and Provide a Comprehensive Corporate Update

2019-10-28 07:45:05 | NurOwn® Data Safety Monitoring Board Recommends ALS Phase 3 Clinical Trial Continue

2019-10-25 01:00:05 | BrainStorm Cell Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

2019-10-24 08:45:58 | BrainStorm Cell Therapeutics’ President and CEO to be Featured as Keynote Speaker at Cell Series UK 2019

2019-10-23 01:00:05 | BrainStorm Cell Therapeutics Presentations at Neuromuscular Drug Development Summit

2019-10-11 01:00:00 | BrainStorm’s NurOwn® Phase 3 ALS Clinical Trial Now Fully Enrolled

2019-10-07 08:04:26 | BrainStorm Announces Notice of US Patent Allowance for NurOwn® Cellular Therapeutic Technology Platform

2019-10-02 06:45:00 | BrainStorm Cell Therapeutics to Present NurOwn® Phase 2 Biomarker Data at North East Amyotrophic Lateral Sclerosis NEALS 18th Annual Meeting

2019-09-27 04:00:00 | BrainStorm Cell Therapeutics Announces Support for FDA Guidelines on ALS Drug Development

2019-09-19 09:19:48 | Is Brainstorm Cell Therapeutics Inc. NASDAQ:BCLI Growing Too Fast?

2019-09-09 01:00:00 | BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer